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Introduction: Inhalation of antigen in atopic asthma induces early (EAR) and late asthmatic responses
(LARs), inﬂammatory cell inﬁltration and airways hyperresponsiveness (AHR). Previously, we have established
a protocol of sensitisation and subsequent ovalbumin (Ova) inhalation challenge in guinea-pigs which induced
these 4 features (Smith & Broadley, 2007). However, the responses of guinea-pigs to Ova challenge have recently
declined, producing no LAR or AHR and diminished EAR and cells. By making cumulative modiﬁcations to the
protocol, we sought to restore these features. Methods: Guinea-pigs were sensitised with Ova (i.p. 100 or
150 μg) on days 1 and 5 or days 1, 4 and 7 and challenged with nebulised Ova (100 or 300 μg/ml, 1 h) on day
15. Airway function was measured in conscious guinea-pigs by whole-body plethysmography to record speciﬁc
airway conductance (sGaw). Airway responsiveness to aerosolized histamine (0.3 mM) was determined before
and 24 h after Ova challenge. Bronchoalveolar lavage was performed for total and differential inﬂammatory cell
counts. Lung sections were stained for counting of eosinophils. Results: Lack of AHR and LAR with the original
protocol was conﬁrmed. Increasing the Ova challenge concentration from 100 to 300 μg/ml restored AHR and
eosinophils and increased the peak of the EAR. Increasing the number of sensitisation injections from 2 to 3
did not alter the responses. Increasing the Ova sensitisation concentration from 100 to 150 μg signiﬁcantly in-
creased total cells, particularly eosinophils. A LAR was revealed and lymphocytes and eosinophils increased
when either the Al(OH)3 concentration was increased or the duration between the ﬁnal sensitisation injection
and Ova challengewas extended from 15 to 21 days.Discussion: This study has shown that declining allergic re-
sponses to Ova in guinea-pigs could be restored by increasing the sensitisation and challenge conditions. It has
also demonstrated an important dissociation between EAR, LAR, AHR and inﬂammation.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Asthma is now recognised as a heterogeneous disease with multiple
pathologies. Allergic asthma is characterised by early and late asthmatic
responses (EARs and LARs) following allergen challenge (O'Byrne,
2009). The EAR is an immediate bronchoconstriction to allergen and usu-
ally resolveswithin theﬁrst couple of hours (Leigh et al., 2002). The LAR is
a temporally separate anddelayedbronchoconstriction, seen in 50%of pa-
tients 3–8 h after allergen challenge (Galli, Tsai, & Piliponsky, 2008;
O'Byrne, 2009). These responses demonstrate large Inter-subject variabil-
ity (Kopferschmitt-Kubler, Bigot, & Pauli, 1987), which does not appear to
have been examined in animal models. The late asthmatic response is
followed by the development of airways hyperresponsiveness (AHR), ane asthmatic response; AHR, air-
c airway conductance.
y, Cardiff University, Redwood
ngdom. Tel.:+44 2920 875832.
).
. This is an open access article underincreased response to a bronchoconstrictor stimulus such as histamine
(Cockcroft & Davis, 2006). These responses are also accompanied by pul-
monary inﬂammation, as manifested by an accumulation of eosinophils,
macrophages and lymphocytes in lung parenchyma tissue (Nabe et al.,
2005). Speciﬁcally, eosinophils are important in the development of late
asthmatic responses and AHR (Gauvreau, Watson, & O'Byrne, 1999;
Homma, Bates, & Irvin, 2005).
Allergen challenge protocols, using antigens such as ovalbumin
(Ova) are used to model characteristics of asthma in guinea-pigs
(Buels, Jacoby, & Fryer, 2012; Evans et al., 2012; Lee, Kim, & Kim,
2013). Sensitisation to Ova is usually achieved by intraperitoneal
administration with an adjuvant such as aluminium hydroxide
(Lindblad, 2004). Animals are then given several weeks for antibodies
(immunoglobulins, IgE and IgG) and for immune responses to develop.
Re-exposure to Ova, generally by the inhaled route then triggers the
effector phase (Chang, Gong, Chen, & Mak, 2011). Lung function can
be measured in conscious, spontaneously breathing animals using
whole body plethysmography which allows for assessment of multiple
functional responses in the same animal over several days.the CC BY license (http://creativecommons.org/licenses/by/3.0/).
86 A.P.P. Lowe et al. / Journal of Pharmacological and Toxicological Methods 72 (2015) 85–93Mice are the most commonly used species for modelling aspects of
asthma, especially inﬂammation. Guinea-pigs are no longer used as
widely but represent valuable models, especially for functional parame-
ters such as the EAR and LAR (reviewed in Canning & Chou, 2008).
Guinea-pigs have a similar distribution of mast cells, to humans (Fuchs
et al., 2012). Also, the EAR bronchoconstriction is pronounced andmedi-
ated by histamine, cysteinyl leukotrienes and prostaglandins in both spe-
cies, contrasting with mice where the EAR bronchoconstriction is
minimal and mediated by 5-HT (Fernandez-Rodriguez, Ford, Broadley,
& Kidd, 2008; Moffatt, Cocks, & Page, 2004; Ressmeyer et al., 2006;
Zosky et al., 2008). Several groups have demonstrated isolated character-
istics of asthma such as AHR, EAR and LAR in guinea-pigs (Riley et al.,
2013; Suda et al., 2009). However, most studies do not assess all of
these characteristics in the same model together with inﬂammatory
cell recruitment, which has potential limitations for using them to assess
drug efﬁcacy of novel treatments (Stevenson&Birrell, 2011).Within this
laboratory, amodel demonstrating an EAR, LAR, AHR and airway inﬂam-
mation to Ova challenge in guinea-pigs has been developed (Evans et al.,
2012). However, this model has required optimisation on several occa-
sions over the years to continue to produce these features. Lewis,
Johnson, andBroadley (1996)modiﬁed the allergen challenge conditions
to stop the need for mepyramine, which prevents fatal anaphylaxis.
Smith and Broadley (2007)modiﬁed the sensitisation conditions because
of the loss of key features over time. They increased the amount of Ova
used and the number of injections given. This restored the EAR, LAR and
AHR to Ova challenge. Five years later, at the beginning of the present
study the responses had again waned with a loss of the LAR and AHR.
The aim of this study was to re-establish an acute guinea-pig model
of asthma displaying early and late asthmatic responses, airway
hyperresponsiveness and airway inﬂammation as demonstrated by
Smith and Broadley (2007) and Evans et al. (2012).
2. Materials and methods
All chemicals were obtained from Sigma-Aldrich, UK or Fisher-
Scientiﬁc, UK unless stated otherwise.
2.1. Animal husbandry
Male Dunkin-Hartley guinea-pigs, 200–300 g were purchased from
Harlan Ltd, UK or Charles River, Germany. Guinea-pigs were housed in
pathogen free conditions with 12 h light/dark cycles. All procedures were
carried out in accordance with Home ofﬁce license conditions of the
Animals (Scientiﬁc Procedures) Act 1986 covering animal husbandry
and severity limits and EU Directive 2010/63/EU for animal experiments.
2.2. Ovalbumin sensitisation and challenge
Guinea-pigs were sensitised by bilateral intra-peritoneal injections
of a solution containing ovalbumin (Ova), VWR (catalogue number
20771.236, UK, 100 or 150 μg) and aluminium hydroxide (Al(OH)3,
Sigma-Aldrich, UK, 100 or 150 mg) in 1 ml of normal saline on days 1
and 5 or days 1, 4 and 7.
Guinea-pigs were exposed to inhaled ovalbumin (100 μg/ml or
300 μg/ml) ondays 15 or 21. Exposurewas performed in a Perspex expo-
sure chamber (15 × 30 × 15 cm) using a DeVilbiss nebuliser, delivered at
a rate of 0.3 ml/min-1 and at an air pressure of 20 ib p.s.i. Guinea-pigs
were exposed for 1 h. Control groups of guinea-pigs were sensitised by
the same protocols and exposed to aerosolised saline. Lung function
was recorded at intervals for 12 h and at 24 h post-challenge, the animals
being removed from the chamber after each determination.
2.3. Ovalbumin protocols
Six different Ova sensitisation and challenge conditions were used
based on the original protocol of Smith and Broadley (2007). Thisprotocol is referred to as protocol 1. Changes were made cumulatively
from protocols 1 to 5. Protocol 6 is amodiﬁcation of protocol 4 (Table 1).
2.4. Non-invasive measurement of speciﬁc airway conductance
Airway function was measured in conscious, spontaneously breath-
ing guinea-pigs using non-invasive double chamber plethysmography
(PY-5551, Buxco systems, USA) tomeasure speciﬁc airway conductance
(sGaw).
2.5. Airway response to histamine
Airway responses to aerosolized histamine were determined before
and 24 h after Ova challenge usingwhole body plethysmography. Hista-
mine (0.3 mM) was nebulised (Buxco nebuliser) direct to the nasal
component of the plethysmograph chamber at a rate of 0.5 l perminute,
2 min nebulisation, and 10% duty setting per chamber. This nebulizer
protocol evokes minimal bronchoconstriction in naïve guinea-pigs and
before Ova challenge of sensitised animals. Lung functionwasmeasured
before histamine inhalation and at 0, 5 and 10 min post-histamine
exposure.
2.6. Pulmonary inﬂammation
Following the ﬁnal histamine challenge, guinea-pigs were sacriﬁced
by an intra-peritoneal overdose of sodium pentobarbitone (Euthatal
400 mg/kg). Guinea-pigs were then bled via severance of a carotid ar-
tery and subsequently a polypropylene cannula was inserted into the
trachea. Bronchoalveolar lavage was performed using normal saline
(1 ml per 100 g of guinea-pig weight) instilled through the cannula
for 3 min before withdrawal. This process was then repeated, the
samples pooled and total number of cells/ml counted using a Neubauer
haemocytometer. Differential cell counts were performed after
centrifuging 100 μl of undiluted lavage ﬂuid using a Shandon cytospin
onto glassmicroscope slides, at 110 g for 7min. Slideswere subsequent-
ly stained with 1.5% Leishman's solution in 100% methanol for 6 min.
Leukocyte subpopulations counted included eosinophils, macrophages,
lymphocytes and neutrophils. A minimum of 200 cells per slide were
counted.
2.7. Tissue eosinophilia
Lung lobe samples were stored in 4% formaldehyde and 1–2 mmbi-
lateral sections cut. Samples were dehydrated in increasing concentra-
tions of ethanol and then chloroform. Tissue sections were then set
into wax blocks using molten parafﬁn. 5 μm sections were cut using a
microtome and mounted on poly-L-lysine-coated slides. Slides were
stained using the Sirius red staining protocol which allows the identiﬁ-
cation of eosinophils (Meyerholz, Grifﬁn, Castilow, & Varga, 2009). The
number of eosinophils was counted per ﬁeld of view magniﬁcation.
Four ﬁelds of view were counted per animal. Eosinophils were deﬁned
as cells demonstrating a cytoplasm staining an intense red with dark
bi-lobed nuclei.
2.8. Data analysis
All lung function data were plotted as a percentage of baseline to
take into account the individual differences in guinea-pig baseline
sGaw values. To account for differences in the timing of allergen
responses during the early (0–6 h) and late (6–12 h) phases, sGaw
was also expressed as the peak bronchoconstriction, displayed as a his-
togram next to a time course plot. Results are plotted as the mean ±
standard error of the mean (SEM). Student's t-tests were used for the
comparison of differences between groups or data points. One way
analysis of variance (ANOVA) followed by a Dunnett's post-test was
Table 1
The six ovalbumin protocols used, with cumulative modiﬁcations from the previous pro-
tocol highlighted in grey shading. Protocol 6 is a modiﬁcation of protocol 4.
Protocol
Protocol 1
Ova
challenge
dose
100µg/ml
No. of
sensitisations
2
Ova
sensitisation
dose
100µg/ml
(Al (OH)3)
sensitisation
dose
100mg/ml
Challenge day
Day 15
Protocol 2 300µg/ml 2 100µg/ml 100mg/ml Day 15
Protocol 3 300µg/ml 3 100µg/ml 100mg/ml Day 15
Protocol 4 300µg/ml 3 150µg/ml 100mg/ml Day 15
Protocol 5 300µg/ml 3 150µg/ml 150mg/ml Day 15
Protocol 6 300µg/ml 3 150µg/ml 100mg/ml Day 21
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p value less than 0.05 was considered signiﬁcant.
3. Results
3.1. Effect of Ova sensitisation and challenge on airway function
Fig. 1 represents the mean time-course changes in sGaw over 24 h
following Ova challenge in conscious guinea-pigs sensitised and
challenged with saline or protocols 1–6.
The sensitisation and challenge protocol previously used successful-
ly in this laboratory (Evans et al., 2012; Smith & Broadley, 2007)
was protocol 1, which consisted of sensitisation with 2 injections of
100 μg/ml Ova and 100 mg Al(OH)3, with subsequent 100 μg/ml
Ova challenge. This resulted in an immediate signiﬁcant reduction in
sGaw (−45.6 ± 6.2%), characteristic of an early asthmatic response
(Fig. 1A). This bronchoconstriction did not return to saline-challenged
levels until 2 h post-challenge. No further decreases in sGaw, character-
istic of the late asthmatic response, were observed. Increasing the Ova
challenge concentration to 300 μg/ml (protocol 2, Fig. 1B) increased
the immediate bronchoconstriction (−60.9 ± 2.1%), compared to pro-
tocol 1, which returned to baseline levels 4 h post-challenge. No late
asthmatic response was observed. Increases in the Ova sensitisation
concentration to 150 μg/ml (protocol 4) and the number of injections
(protocol 3) did not alter the airway response (not shown).
Increasing the Al(OH)3 adjuvant concentration to 150 mg (protocol
5, Fig. 1C) did not alter the size or duration of the early asthmatic re-
sponse compared to protocol 4 but produced a late asthmatic response,
characterised by a signiﬁcant decrease in sGaw at 6 h (−17.6 ± 4.6%
compared to−3.8 ± 4.2%). Increasing the time between Ova sensitisa-
tion and challenge, while returning to protocol 4 conditions (protocol 6,
Fig. 1D) signiﬁcantly increased the duration of the early asthmatic re-
sponse compared to protocol 4, with a signiﬁcant decrease in sGaw at
all time points from 45 min to 5 h post-challenge. This group also dem-
onstrated a late asthmatic response between 8 and 9 h. The mean peak
response during this period was−19.9 ± 4.9% compared to protocol 4,
1.3 ± 2.6%.
3.2. Effect of Ova sensitisation and challenge on airway response to histamine
No signiﬁcant bronchoconstriction to histamine was observed in any
experimental animal 24 h before Ova or saline challenge (Fig. 2). Small
changes were observed in some groups which represent the normal
variation in sensitivity to a threshold concentration of histamine. In ani-
mals challenged with saline, no histamine-induced bronchoconstriction
was observed 24 h after saline (Fig. 2A). Animals sensitisedwith 2 injec-
tions of 100 μg/ml Ova and 100 mg Al(OH)3 and challenged with
100 μg/ml Ova (protocol 1, Fig. 2B) also lacked histamine-induced
bronchoconstriction, indicating the absence of AHR. Increasing the
Ova challenge concentration to 300 μg/ml (protocol 2, Fig. 2C) caused
a signiﬁcant bronchoconstriction to histamine 24 h after Ova challenge(−38.5 ± 7.9% compared to pre-−4.1 ± 2.3%) which resolved within
10 min. Increasing the Al(OH)3 concentration (protocol 5, Fig. 2D), in-
creasing Ova sensitisation concentration (protocol 4) and the number
of injections (protocol 3) did not further alter the nature of this
response (data not shown).
Increasing the time between Ova sensitisation and challenge (proto-
col 6, Fig. 2E) increased the size of the immediate bronchoconstriction to
histamine 24 h post-challenge (−53.9.4 ± 11.4%) compared to pre-Ova
challenge, (−10.1 ± 2.4%). The duration of the bronchoconstriction
was also increased, at 10 min into the response, the bronchoconstriction
was −26.7 ± 11.4% compared to the pre-Ova challenge level of
1.6 ± 2.7%.
3.3. Effect of Ova sensitisation and challenge on pulmonary inﬂammation
100 μg/ml Ova challenge signiﬁcantly increased total lavage cells
(protocol 1, Fig. 3A, 3.2 ± 0.5 × 106/ml) compared to saline (1.6 ±
0.13 × 106/ml). Eosinophils (Fig. 3C) made up most of this increase
(1.3 ± 0.3 × 106/ml) compared to saline (0.05 ± 0.01 × 106/ml).
Increasing the Ova challenge concentration (protocol 2) signiﬁcantly
increased the total cell numbers (5.3± 0.4 × 106/ml) compared to pro-
tocol 1 (3.2 ± 0.5 × 106/ml). Eosinophils were signiﬁcantly elevated
(2.0 ± 0.2 × 106/ml) compared to protocol 1 (1.3 ± 0.3 × 106/ml).
Increasing the number of 100 μg Ova sensitisation injections (protocol
3) had no effect on any cell type measured.
Increasing the Ova sensitisation concentration to 150 μg
(protocol 4) signiﬁcantly increased total cells (8.3 ± 0.9 × 106/ml)
compared to protocol 3 (4.8 ± 0.4 × 106/ml). Eosinophils (3.9 ± 0.3 ×
106/ml compared to 2.4 ± 0.3 × 106/ml) and macrophages (Fig. 3B,
3.5 ± 0.3 × 106/ml compared to 2.2 ± 0.2 × 106/ml) were also signiﬁ-
cantly increased. Increasing the Al(OH)3 sensitisation concentration to
150 mg (protocol 5) signiﬁcantly increased eosinophils (6.9 ± 0.8 ×
106/ml) compared to protocol 4 (4.6 ± 0.5 × 106/ml). Lymphocytes
(Fig. 3D) were also signiﬁcantly increased (0.15 ± 0.02 × 106/ml) com-
pared to protocol 4 (0.3 ± 0.01 × 106/ml).
Increasing the duration between Ova sensitisation and challenge
(protocol 6) to 21days did not signiﬁcantly change the total cell numbers.
Lymphocytes (0.37 ± 0.07 × 106/ml) and eosinophils (5.5 ± 0.2 ×
106/ml) were signiﬁcantly increased compared to animals challenged
on day 15 (protocol 4, 0.04 ± 0.01 × 106 and 3.9 ± 0.3 × 106/ml,
respectively). Neutrophils (Fig. 3E) were unchanged in all protocols.
3.4. Effect of Ova sensitisation and challenge on tissue eosinophilia
Fig. 4A–G shows typical photomicrographs for lung sections stained
with Sirius red to identify eosinophils. Fig. 4H shows the number of
eosinophils counted per ﬁeld of view. A progressive trend for increased
eosinophil numberswas observedwith cumulativemodiﬁcations to the
Ova sensitisation and challenge protocol. This reached signiﬁcance
compared to saline when the number of sensitisation injections was in-
creased to 3 (187.4 ± 40.2, saline: 27.0 ± 7.4). All subsequent modiﬁ-
cations maintained elevated eosinophilia compared to saline but did
not further increase it (173.7 ± 29.1, 180.2 ± 13.0 and 185.8 ± 20.5
respectively).
3.5. Variability of airway responses to Ova
Fig. 5 demonstrates the variability between guinea-pigs in the
timing of the early and late asthmatic responses, exempliﬁed by data
from the ﬁnal sensitisation and challenge protocol used (protocol 6).
Each guinea-pig displays a different EAR and LAR temporal proﬁle.
4. Discussion
This study has conﬁrmed the loss over time of essential features of
asthma in a guinea-pig model that had previously shown early and
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Fig. 2.Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycleswith 0.5 LPM ﬂowper chamber over 2min, 1min drying period) to guinea-
pigs sensitisedwith 2 injections of 100 μg/ml ovalbumin (Ova) and 100mg Al(OH)3 and challengedwith on day 15 with saline (saline), 100 μg/ml Ova (protocol 1), 300 μg/ml Ova (pro-
tocol 2), 3 injections of 150 μg ovalbumin (Ova) and 150mg Al(OH)3 and challenged on day 15with 300 μg/ml (protocol 5) or sensitisedwith 3 injections of 150 μg ovalbumin (Ova) and
100 mg Al(OH)3 on day 21 (protocol 6). Values were recorded 24 pre- and post-Ova or saline challenge. Mean changes in sGaw are expressed as mean ± SEM percentage change from
baseline. A negative value represents a bronchoconstriction. N = 6; * signiﬁcantly different from time-paired pre-Ova challenge values p b 0.05, **p b 0.01; performed with a two tailed
Student's t-test.
89A.P.P. Lowe et al. / Journal of Pharmacological and Toxicological Methods 72 (2015) 85–93late asthmatic responses, AHR and airway inﬂammation. By making
cumulative modiﬁcations to the allergen sensitisation and challenge
conditions, however, it has been possible to restore these four features
of the model.Fig. 1.Themean time-courses for sGawvalues in guinea-pigs sensitisedwith 2 injections of 100
100 μg/ml (protocol 1), 300 μg/ml Ova (protocol 2), sensitisedwith 3 injections of 150 μg ovalbu
3 injections of 150 μg ovalbumin (Ova) and 150 mg Al(OH)3 and challenged on day 15 with 3
day 21 (protocol 6). The histogram represents the maximum bronchoconstriction values re
(LAR) (6–12 h). Mean changes in sGaw are expressed asmean± SEMpercentage change from
from paired protocol p b 0.05, **p b 0.01, ***p b 0.001 performed with a two tailed Student's tSensitisation of guinea-pigs with 2 injections of 100 μg/ml Ova
and 100 mg Al(OH)3 and subsequent Ova challenge on day 15 with
100 μg/ml Ova (protocol 1) did not evoke a LAR or AHR. A small early
phase immediately after allergen challenge and increased eosinophilμg/ml ovalbumin (Ova) and 100mgAl(OH)3 and challenged on day 15with saline (saline),
min (Ova) and 100mgAl(OH)3 and challenged onday 15with 300 μg/ml Ova (protocol 4),
00 μg/ml (protocol 5) or 3 injections of 150 μg ovalbumin (Ova) and 100 mg Al(OH)3 on
corded during the early asthmatic response (EAR) (0–6 h) and late asthmatic response
baseline. A negative value represents a bronchoconstriction. N=6; * signiﬁcantly different
-test.
Fig. 3. The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil (E) counts in bronchoalveolar ﬂuid in guinea-pigs sensitised with 2 injections of 100 μg/ml
ovalbumin (Ova) and 100 mg Al(OH)3 and challenged with on day 15 with saline (sal), 100 μg/ml (protocol 1), 300 μg/ml Ova (protocol 2), sensitised with 3 injections of 100 μg/ml
ovalbumin (Ova) and 100 mg Al(OH)3 and challenged on day 15 with 300 μg/ml Ova (protocol 3), sensitised with 3 injections of 150 μg ovalbumin (Ova) and 100 mg Al(OH)3 and
challenged on day 15 with 300 μg/ml Ova (protocol 4), 3 injections of 150 μg ovalbumin (Ova) and 150mg Al(OH)3 and challenged on day 15with 300 μg/ml (protocol 5) or 3 injections
of 150 μg ovalbumin (Ova) and 100mg Al(OH)3 on day 21 (protocol 6). N=6; * signiﬁcantly different from the previous protocol (protocol 4 in the case of protocol 6) p b 0.05, **p b 0.01,
***p b 0.001; performed with a two tailed Student's t-test.
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previously been effective at producing the full range of allergic re-
sponses (Evans et al., 2012; Smith & Broadley, 2007). The present
work suggests that there has been a progressive loss of sensitivity of
guinea-pigs to ovalbumin over time. The reason for the deterioration
of allergic responses remains unknown although it does not appear to
be related to any changes in diet, shipping, ovalbumin or season. The
process does seem to be an ongoing phenomenon as we have reported
the need for modiﬁcations on two previous occasions (Lewis et al.,
1996; Smith & Broadley, 2007).
Increasing the Ova challenge concentration 3-fold increased the
peak bronchoconstriction of the EAR and induced AHR 24 h afterallergen challenge. A further increase in total cell and eosinophil num-
bers was seen. The addition of an extra sensitisation injection did not
alter functional responses but increased bronchial tissue eosinophil
numbers,with no signiﬁcant change in lavage eosinophil numbers. Sim-
ilarly, increasing the Ova sensitisation concentration did not alter func-
tional responses but did increase total and eosinophil lavage numbers.
Having increased the Ova sensitisation and challenge concentra-
tions, either increasing the Al(OH)3 concentration during sensitisation
or increasing the duration between Ova sensitisation and challenge
was able to induce the full range of functional and inﬂammatory re-
sponses; EAR, LAR, AHR and pulmonary inﬂammation. The increase in
Al(OH)3 concentration revealed a LAR at 6 h post-allergen challenge,
Fig. 4.Guinea-pig lung tissue sections stainedwith Sirius red. Sensitisation and challenge varied accordinglyA2×100 μg/mlOva/100mgAl(OH)3with saline challenge (saline). B 2×100 μg/ml
Ova/100 mg Al(OH)3 with 100 μg/ml Ova challenge (protocol 1). C 2 × 100 μg/ml Ova/100 mg Al(OH)3 with 300 μg/ml Ova challenge (protocol 2). D 3 × 100 μg/ml Ova/100 mg Al(OH)3
with 300 μg/ml Ova challenge (protocol 3). E 3 × 150 μg Ova/100 mg Al(OH)3 with 300 μg/ml Ova challenge (protocol 4). F 3 × 150 μg Ova/150 mg Al(OH)3 with 300 μg/ml Ova challenge
(protocol 5). G 3 × 100 μg/ml Ova/100 mg Al(OH)3 with 300 μg/ml Ova challenge on day 21 (protocol 6). H the number of tissue eosinophils (per ﬁeld of view). Original magniﬁcation
200×; bar=50 μm). L: lumen; ASM: airway smoothmuscle; E: epithelium. Eosinophils (Eos)were deﬁned as cells demonstrating a cytoplasm staining an intense redwith dark bi-lobed nuclei.
N = 4–6; ** signiﬁcantly different to saline p b 0.01; ***p b 0.001; performed with one-way analysis of variance with Dunnett's post-test.
91A.P.P. Lowe et al. / Journal of Pharmacological and Toxicological Methods 72 (2015) 85–93lasting for 1 h. Extending the time between allergen sensitisation and
challenge prolonged the EAR and LAR, the latter characterised by a
bronchoconstriction lasting 2 h. AHR to histaminewasmore pronounced
in guinea-pigs with an increased duration between sensitisation and
challenge but not signiﬁcantly so. This protocol also signiﬁcantly
increased lymphocyte numbers when compared to increasing the
Al(OH)3 concentration.
Therefore, 3 injections of 150 μg Ova and 100 mg Al(OH)3 followed
by 300 μg/ml Ova challenge on day 21 can be seen to produce an EAR
and LAR, a robust AHR to histamine and elevatedmacrophage, lympho-
cyte and eosinophil numbers in lavage and eosinophils in the bronchi.
The early asthmatic response was consistently observed with all
protocols and therefore appears to be reliably induced by lower levels
of sensitisation and challenge. Allergen challenge in sensitised animals
causes mast cell degranulation by the crosslinking of FcεR1 receptors,
releasing histamine, leukotrienes, prostaglandins and platelet activating
factor whichmediate the EAR bronchoconstriction (Beasley et al., 1989;
Björck & Dahlén, 1993; Smith, Rubin, & Patterson, 1988; Zielen et al.,
2013). We believe that the immediate fall in sGaw seen with this
model represents the EAR since earlier studies with this model show
that it is associated with histamine release (Toward & Broadley, 2004).
Furthermore, the EAR is resistant to corticosteroids which reduce theFig. 5. The time-course values of sGaw in individual guinea-pigs sensitised with 3 injec-
tions of a suspension of 150 μg Ova and 100 mg Al(OH)3 and challenged with 300 μg/ml
Ova on day 21 (protocol 6). Changes in sGaw are expressed as percentage change from
baseline. A negative value represents a bronchoconstriction. Theﬁgure illustrates the indi-
vidual variability in the early and late asthmatic responses toOva challenge in guinea-pigs.LAR (Evans et al., 2012). In the present study, increasing the Ova
challenge dose 3-fold increased the magnitude of the immediate
bronchoconstriction, possibly as a result of increased FcεR1 crosslinking
and release of bronchoconstrictor substances (Frandsen, Krohn,
Hoffmann, & Schiøtz, 2013; MacGlashan, 1993). Smith and Broadley
(2007) demonstrated that increasing the concentration of Ova used in
sensitisation can also further decrease sGaw immediately after allergen
challenge. This was possibly due to enhanced IgE production following
sensitisation (Frandsen et al., 2013).
Mast cells and basophils release a range of additional factors
including cytokines, chemokines and growth factors during the EAR,
which have a role in later events such as lymphocyte activation and eo-
sinophil inﬂux (Amin, 2012; Bradding et al., 1994; Nouri-Aria et al.,
2001). In turn, inﬂammatory cells release further mediators including
TNF-α and eosinophil cationic protein which increase sensitivity to
bronchoconstrictor agents (Homma et al., 2005; Makwana, Gozzard,
Spina, & Page, 2012). The latter, released from eosinophils, can damage
the epithelium and expose underlying sensory nerves, increasing sensi-
tivity to bronchoconstrictor stimuli like histamine (Hommaet al., 2005).
In the present study, lavage eosinophil numbers increased at 24 h, con-
comitant with the development of AHR. However, this relationship is
not clear cut since the original Ova protocol used in this study (protocol
1) resulted in signiﬁcant eosinophilia but with no AHR. Similarly, in
other models and humans, eosinophilia and AHR have been observed
to be dissociated (Birrell, Battram, Woodman, McCluskie, & Belvisi,
2003; Leckie et al., 2000). Cell counts can differ between lavage ﬂuid
and lung sections which could explain this result (Maestrelli et al.,
1995). However, it was observed in this study that eosinophil numbers
weremoderately related between assessmentmethods, although tissue
assessment seemed less likely to discern small changes. This suggests
that the number of eosinophils may not be important in AHR. It does
not discount that some other factor such as eosinophil activation status
could be more critical. The AHR observed in the present study can be
assumed to be non-speciﬁc as previous studies with earlier version of
our model have shown increases in sensitivity to a wide range of
spasmogens (Spruntulis & Broadley, 1999).
Allergen sensitisation begins with the uptake of antigen by antigen
presenting cells (APCs) which process and present it to lymphocytes,
which in turn undergo either apoptosis or activation (Hammad et al.,
2010). Activation leads to the development of an allergic immune
92 A.P.P. Lowe et al. / Journal of Pharmacological and Toxicological Methods 72 (2015) 85–93response. The extent of this response is dependent on the sensitisation
conditions. Increased immune stimulation during sensitisation results
in increased lymphocyte priming and consequently stronger responses
when the allergen is re-encountered. In the present study, cumulative
modiﬁcations to the sensitisation conditions including increased num-
ber of injections, Ova concentration and Al(OH)3 concentration caused
a progressive increase in total and eosinophil counts. Al(OH)3 enhances
sensitisation to antigens via a variety of mechanisms including
enhanced antigen uptake, T-cell proliferation, uric acid formation,
inﬂammasome formation and promotion of Th2 type responses
(Eisenbarth et al., 2002; Kool et al., 2008; Moreﬁeld et al., 2005;
Sokolovska, Hem, & HogenEsch, 2007). In accordance with this, in-
creased Al(OH)3 concentration signiﬁcantly increased lymphocyte in-
ﬂux and induced the development of a LAR, suggestive of enhanced
sensitisation. Al(OH)3 produces these effects in a concentration-
dependent manner, with an excess of free adjuvant required for
increased immune stimulation (Majgaard Jensen & Koch, 1988).
Allergen sensitisation takes several weeks to develop, involving the
production of IgE and activation of lymphocytes. Increasing the time be-
tween allergen sensitisation and challenge in the current study in-
creased several of the parameters measured including the duration of
the EAR, lymphocyte and eosinophil numbers and induced a LAR. This
suggests that in previous protocols allergen sensitisationwas still ongo-
ing during challenge and an increased period between the two was re-
quired for the generation of a full response. This modiﬁcation restores
the gap between sensitisation and challenge to the duration used in
this laboratory's original sensitisation protocol (Lewis et al., 1996)
which had decreased with previous modiﬁcations (Smith & Broadley,
2007). Notwithstanding the reduced time between ﬁnal sensitisation
dose and challenge when increasing to 3 sensitisations, there was still
a loss of allergic responses with protocol 1 compared to previous stud-
ies. The addition of a 3rd sensitisation injection on day 7 resulted in a
further shortening of the sensitisation period to 8 days. 8 days between
the ﬁnal allergen sensitisation and challengemay not be enough time to
produce a full immunological response, except when the sensitisation
conditions are increased to a certain extent, as seen in guinea-pigs
sensitised with an increased adjuvant concentration.
The late asthmatic response is associatedwith an inﬂux of a range of
inﬂammatory cells including eosinophils and T lymphocytes (Nabe
et al., 2005). Eosinophilia is correlated with the magnitude of the LAR,
both being signiﬁcantly increased in humans and animalmodels follow-
ing allergen challenge (Dente et al., 2008; Evans et al., 2012; Gauvreau
et al., 1999). Additionally, corticosteroids which reduce eosinophil and
lymphocyte numbers also decrease the LAR (Kawayama et al., 2008;
Leigh et al., 2002). The present study demonstrated that increases in
both eosinophils and lymphocytes coincided with the development of
a LAR, supporting a link between these parameters. Althoughwe exam-
ined cellular inﬂux at 24 h after Ova challenge and not at the peak of the
LAR, our previous studies with earlier versions of this model have
shown signiﬁcant increases in neutrophils, macrophages and eosino-
phils at the time of the LAR (Danahay, Broadley, McCabe, Nials, &
Sanjar, 1999; Toward & Broadley, 2004). However, not all results from
this study support this relationship; eosinophils were also increased in
protocols 1–4, which did not demonstrate a LAR. Studies in humans
have also demonstrated similar results. Blocking OX40, a co-stimulator
receptor important in generating allergic responses signiﬁcantly atten-
uated eosinophiliawith no effect on the LAR (Gauvreau et al., 2014). Ad-
ditionally, older studies have demonstrated that anti-IL-5 therapy
reduced eosinophilia but not AHR and the LAR in humans (Leckie
et al., 2000). Overall, the role of eosinophils in the LAR remains uncer-
tain. The investigation of factors such as the activation status of eosino-
phils may be more revealing than cell number. Substances released
from eosinophils including platelet activating factor and eosinophil cat-
ionic protein can directly cause LAR bronchoconstriction and therefore
may correlate better with LAR (Evans, Barnes, Cluzel, & O'Connor,
1997; Gauvreau et al., 2011). There are also recent suggestions thatcentral reﬂexes may drive a LAR in some models of allergen challenge
in guinea-pigs (Smit et al., 2014).
Functional responses to allergens demonstrate low intra-subject but
high inter-subject variation in humans (Kopferschmitt-Kubler et al.,
1987). The reasons for this variability are likely to be multifactorial in-
cluding gender and total and allergen-speciﬁc IgE levels (Petersen,
Mosbech, & Skov, 1996). Examination of the individual guinea-pig re-
sponses in the ﬁnal protocol of the present study highlights how this
phenomenon is also observed in animal models. This emphasises the
need for including sufﬁcient numbers in experimental groups to have
sufﬁcient statistical power, as well as multiple measurements to
evaluate peak responses over a wide temporal window.
In conclusion, this study has demonstrated a dissociation between
eosinophil inﬂux and LAR as well as AHR. It has highlighted that
assessing parameters in isolation, such as inﬂammatory cell inﬂux in
bronchoalveolar lavage ﬂuid, would fail to identify if other key compo-
nents of the allergic response and its functional outcomes (e.g. AHR)
are absent. These models would be inadequate for examining the com-
plex relationship between inﬂammatory and functional parameters that
would be required in preclinical testing of novel therapeutics or identi-
ﬁcation of potential therapeutic mechanisms. Finally, we achieved our
objective of restoring a full proﬁle of functional and inﬂammatory
responses by manipulating the sensitisation and challenge protocols.
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